Top-Rated StocksTop-RatedNASDAQ:EXAS Exact Sciences (EXAS) Stock Price, News & Analysis $59.11 -1.80 (-2.96%) (As of 09/6/2024 ET) Add Compare Share Share Today's Range$58.29â–Ľ$61.0050-Day Range$42.43â–Ľ$62.2652-Week Range$40.62â–Ľ$81.28Volume1.66 million shsAverage Volume2.61 million shsMarket Capitalization$10.91 billionP/E RatioN/ADividend YieldN/APrice Target$78.50 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends Get Exact Sciences alerts: Email Address Exact Sciences MarketRank™ Stock AnalysisAnalyst RatingBuy3.00 Rating ScoreUpside/Downside32.8% Upside$78.50 Price TargetShort InterestBearish7.49% of Shares Sold ShortDividend StrengthN/ASustainability-0.83Upright™ Environmental ScoreNews Sentiment0.76Based on 9 Articles This WeekInsider TradingN/AProj. Earnings GrowthGrowingFrom ($0.87) to ($0.06) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.4.45 out of 5 starsMedical Sector99th out of 910 stocksMedical Laboratories Industry3rd out of 18 stocks 4.5 Analyst's Opinion Consensus RatingExact Sciences has received a consensus rating of Buy. The company's average rating score is 3.00, and is based on 15 buy ratings, no hold ratings, and no sell ratings.Amount of Analyst CoverageExact Sciences has been the subject of 7 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Exact Sciences' stock forecast and price target. Previous Next 1.0 Short Interest Percentage of Shares Shorted7.49% of the outstanding shares of Exact Sciences have been sold short.Short Interest Ratio / Days to CoverExact Sciences has a short interest ratio ("days to cover") of 4.8.Change versus previous monthShort interest in Exact Sciences has recently increased by 1.69%, indicating that investor sentiment is decreasing. Previous Next 0.0 Dividend Strength Dividend YieldExact Sciences does not currently pay a dividend.Dividend GrowthExact Sciences does not have a long track record of dividend growth. Previous Next 4.7 Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreExact Sciences has received a 74.50% net impact score from Upright. The largest positive contribution comes from its "Physical diseases" impact, which is mostly driven by its "Private genetic testing services", "Biochemical assay kits for colorectal cancer diagnostics", and "Biochemical assay kits for liver cancer diagnostics" products. See details.Environmental SustainabilityThe Environmental Impact score for Exact Sciences is -0.83. Previous Next 3.2 News and Social Media Coverage News SentimentExact Sciences has a news sentiment score of 0.76. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.55 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 9 news articles for Exact Sciences this week, compared to 7 articles on an average week.Search InterestOnly 3 people have searched for EXAS on MarketBeat in the last 30 days. This is a decrease of -91% compared to the previous 30 days.MarketBeat Follows7 people have added Exact Sciences to their MarketBeat watchlist in the last 30 days. This is an increase of 17% compared to the previous 30 days. Previous Next 1.7 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Exact Sciences insiders have not sold or bought any company stock.Percentage Held by InsidersOnly 1.36% of the stock of Exact Sciences is held by insiders.Percentage Held by Institutions88.82% of the stock of Exact Sciences is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Exact Sciences' insider trading history. Previous Next 0.6 Earnings and Valuation Earnings GrowthEarnings for Exact Sciences are expected to grow in the coming year, from ($0.87) to ($0.06) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Exact Sciences is -44.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Exact Sciences is -44.78, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioExact Sciences has a P/B Ratio of 3.42. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Exact Sciences' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Behind the MarketsNASDAQ to crash 50%?During the 2020 Covid Crash he called a market reversal - eleven days before the S&P bottomed out... Now, he's saying there are four major cracks forming in the US economy...Click here to learn more >>> About Exact Sciences Stock (NASDAQ:EXAS)Exact Sciences Corporation provides cancer screening and diagnostic test products in the United States and internationally. The company offers Cologuard, a non-invasive stool-based DNA screening test to detect DNA and hemoglobin biomarkers associated with colorectal cancer and pre-cancer. It also provides Oncotype DX Breast Recurrence Score Test; Oncotype DX Breast DCIS Score Test; Oncotype DX Colon Recurrence Score Test; OncoExTra Test for tumor profiling for patients with advanced, metastatic, refractory, relapsed, or recurrent cancer; and Covid-19 testing services. The company's pipeline products focus on enhancing the Cologuard test's performance characteristics and developing blood and other fluid-based tests. It has license agreements with MAYO Foundation for Medical Education and Research, and Johns Hopkins University. Exact Sciences Corporation was incorporated in 1995 and is headquartered in Madison, Wisconsin.Read More EXAS Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart EXAS Stock News HeadlinesSeptember 5 at 2:22 AM | americanbankingnews.comExact Sciences Co. (NASDAQ:EXAS) Receives Consensus Recommendation of "Buy" from AnalystsSeptember 4 at 9:43 PM | seekingalpha.comExact Sciences Corporation (EXAS) at Wells Fargo 2024 Healthcare Conference - TranscriptSeptember 7, 2024 | Behind the Markets (Ad)â• [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.September 4 at 2:48 AM | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences Amid Promising Cancer Screening Innovations and Strategic AdvantagesSeptember 3, 2024 | ca.finance.yahoo.comEXAS Oct 2024 35.000 putAugust 29, 2024 | msn.comWells Fargo Initiates Coverage of Exact Sciences (EXAS) with Overweight RecommendationAugust 29, 2024 | americanbankingnews.comExact Sciences (NASDAQ:EXAS) Now Covered by Analysts at Wells Fargo & CompanyAugust 28, 2024 | businesswire.comExact Sciences to Participate in September Investor ConferencesSeptember 7, 2024 | Behind the Markets (Ad)â• [URGENT] Buy Alert just triggeredMy absolute favorite stock just hit a critical "buy now" trigger price.August 24, 2024 | finance.yahoo.comShould You Believe in the Growth Potential of Exact Sciences Corporation (EXAS)?August 21, 2024 | msn.comHere's Why Baron Opportunity Fund Sold its Stake in Exact Sciences Corp (EXAS)August 18, 2024 | seekingalpha.comExact Sciences: Cost Optimization And Product StrengthAugust 17, 2024 | finance.yahoo.comExact Sciences data finds Cologuard detected almost 600k cancer casesAugust 15, 2024 | nasdaq.comEXACT Sciences Breaks Above 200-Day Moving Average - Bullish for EXASAugust 5, 2024 | markets.businessinsider.comAnalysts Offer Insights on Healthcare Companies: Alignment Healthcare (ALHC), Exact Sciences (EXAS) and Fulcrum Therapeutics (FULC)August 2, 2024 | finance.yahoo.comExact Sciences Corporation (NASDAQ:EXAS) Just Released Its Second-Quarter Earnings: Here's What Analysts ThinkAugust 2, 2024 | markets.businessinsider.comStrong Q2 Performance and Growth Trajectory Justify Buy Rating for Exact SciencesAugust 2, 2024 | markets.businessinsider.comBuy Rating Affirmed for Exact Sciences on Strong Financials and Promising Growth CatalystsSee More Headlines Receive EXAS Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Exact Sciences and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings7/31/2024Today9/07/2024Next Earnings (Estimated)11/06/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Medical laboratories Sub-IndustryBiotechnology Current SymbolNASDAQ:EXAS CUSIP30063P10 CIK1124140 Webwww.exactsciences.com Phone(608) 284-5700Fax608-284-5701Employees6,600Year Founded1995Price Target and Rating Average Stock Price Target$78.50 High Stock Price Target$95.00 Low Stock Price Target$67.00 Potential Upside/Downside+32.8%Consensus RatingBuy Rating Score (0-4)3.00 Research Coverage15 Analysts Profitability EPS (Most Recent Fiscal Year)($1.32) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$-204,150,000.00 Net Margins-6.70% Pretax Margin-6.59% Return on Equity-4.97% Return on Assets-2.41% Debt Debt-to-Equity Ratio0.73 Current Ratio2.17 Quick Ratio1.98 Sales & Book Value Annual Sales$2.61 billion Price / Sales4.18 Cash Flow$0.02 per share Price / Cash Flow3,622.22 Book Value$17.28 per share Price / Book3.42Miscellaneous Outstanding Shares184,530,000Free Float182,020,000Market Cap$10.91 billion OptionableOptionable Beta1.22 Social Links 7 Energy Stocks to Buy and Hold ForeverDo you expect the global demand for energy to shrink?! If not, it's time to take a look at how energy stocks can play a part in your portfolio.Get This Free Report Key ExecutivesMr. Kevin T. Conroy (Age 58)Chairman of The Board & CEO Comp: $1.54MMr. Jeffrey T. Elliott CFA (Age 46)EVP & CFO Comp: $518.13kMs. Sarah Condella (Age 43)Executive Vice President of Human Resources Comp: $742.76kMr. Everett V. Cunningham (Age 58)Chief Commercial Officer Comp: $1.34MDr. Jorge A. Garces Ph.D. (Age 52)Chief Science Officer Mr. Nassar NizamiChief Information OfficerMs. Megan JonesAssociate Manager of Investor RelationsMr. Tim CaprezChief Compliance Counsel & VPMr. James Herriott (Age 44)Senior VP, General Counsel & Secretary Mr. Vic ParkerHead of SalesMore ExecutivesKey CompetitorsPRA Health SciencesNASDAQ:PRAHMedpaceNASDAQ:MEDPCharles River Laboratories InternationalNYSE:CRLPPDNASDAQ:PPDSyneos HealthNASDAQ:SYNHView All CompetitorsInsiders & InstitutionsSanctuary Advisors LLCBought 21,438 shares on 9/5/2024Ownership: 0.012%Cetera Investment AdvisersBought 56,174 shares on 8/22/2024Ownership: 0.089%Truist Financial CorpSold 1,892 shares on 8/21/2024Ownership: 0.009%Kimelman & Baird LLCBought 1,997 shares on 8/19/2024Ownership: 0.001%Creative PlanningBought 4,954 shares on 8/16/2024Ownership: 0.018%View All Insider TransactionsView All Institutional Transactions EXAS Stock Analysis - Frequently Asked Questions How have EXAS shares performed this year? Exact Sciences' stock was trading at $73.98 on January 1st, 2024. Since then, EXAS stock has decreased by 20.1% and is now trading at $59.11. View the best growth stocks for 2024 here. How were Exact Sciences' earnings last quarter? Exact Sciences Co. (NASDAQ:EXAS) announced its quarterly earnings data on Wednesday, July, 31st. The medical research company reported ($0.09) earnings per share for the quarter, topping the consensus estimate of ($0.37) by $0.28. The firm's revenue for the quarter was up 12.4% compared to the same quarter last year. What is Kevin T. Conroy's approval rating as Exact Sciences' CEO? 328 employees have rated Exact Sciences Chief Executive Officer Kevin T. Conroy on Glassdoor.com. Kevin T. Conroy has an approval rating of 97% among the company's employees. This puts Kevin T. Conroy in the top 30% of approval ratings compared to other CEOs of publicly-traded companies. 69.0% of employees surveyed would recommend working at Exact Sciences to a friend. Does Exact Sciences have any subsidiaries? Exact Sciences subsidiaries include these companies: Ashion Analytics, Thrive Earlier Detection Corporation, Base Genomics Limited, Paradigm Diagnostics Inc., Viomics Inc., Biomatrica Inc., Armune BioScience, and more. Who are Exact Sciences' major shareholders? Top institutional investors of Exact Sciences include William Blair Investment Management LLC (2.10%), Ensign Peak Advisors Inc (0.98%), Baillie Gifford & Co. (0.77%) and Armistice Capital LLC (0.76%). Insiders that own company stock include Kevin T Conroy, Sarah Condella, Katherine S Zanotti, James Edward Doyle, Everett Cunningham, D Scott Coward, Daniel J Levangie, Jacob A Orville, Brian Baranick, Jeffrey Thomas Elliott and James Herriott. View institutional ownership trends. How do I buy shares of Exact Sciences? Shares of EXAS stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. What other stocks do shareholders of Exact Sciences own? Based on aggregate information from My MarketBeat watchlists, some other companies that Exact Sciences investors own include Novavax (NVAX), NVIDIA (NVDA), Alibaba Group (BABA), Micron Technology (MU), Salesforce (CRM), PayPal (PYPL) and Block (SQ). This page (NASDAQ:EXAS) was last updated on 9/7/2024 by MarketBeat.com Staff From Our PartnersPerfect Crypto Buying Opportunity for 50 CentsWhen cryptos take a hit, the mom and pop investors run for the hills. But the top investors keep buying wit...Crypto 101 Media | SponsoredThe solution to fast food’s wage hike crisisShake Shack will be closing six California locations in response to the recent $20/hour minimum wage increase,...Deal Maker | SponsoredPre-IPO| 32,481% Growth: First Disruption to $martphones in 15 Years🤳45M Users | 32,481% Growth Rate Get in on the biggest disruption to smartphones in over a decade. Reg A inv...Mode Mobile | SponsoredTim Sykes’ Urgent Trade Alert: “Make this move now”WARNING: 80 Wall Street banks are gearing up for MASSIVE D.C. shock This $2 trillion D.C. shock is NOT abou...Timothy Sykes | SponsoredSay Goodbye to the US DollarThe warning signs are everywhere… According to experts, the United States Dollar is "as good as doomed." ...Sasco Gold LLC | SponsoredElon Musk’s chilling warning for humanityThe 'invasion' I've discovered has nothing to do with the border crisis. What's happening at our southern bord...The Freeport Society | SponsoredThese 5 stocks could soar after November 4thHow to Trade this Crazy Election Year? Simple – Just Focus on These 5 stocks… Now available – a free report...StockEarnings | SponsoredKamala’s Dirty Election Move… RevealedAccording to former advisor to the CIA, the Pentagon and the White House Jim Rickards… Kamala and her puppe...Paradigm Press | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Exact Sciences Co. Please log in to your account or sign up in order to add this asset to your watchlist. Share Exact Sciences With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.